| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.23 | 0.2 |
| mRNA | Nutlin-3 | CCLE | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | 0.069 | 0.2 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.2 |